Innoviva (US:INVA) — Company Overview, News & Financial Data
Innoviva develops innovative biopharmaceuticals to address unmet medical needs through strategic partnerships and investments.
Innoviva
Innoviva (NASDAQ:INVA) specializes in the development and commercialization of bio-pharmaceuticals, focusing on revolutionary drug options in areas of significant unmet medical need. It stands out for its partnerships aimed at advancing its project pipeline while targeting strategic investments to broaden its portfolio in healthcare and biotechnology sectors. The company strives to improve patient outcomes through innovative medicines, applying rigorous science and research to uncover breakthroughs. Innoviva aims to maintain and expand its presence in the healthcare market, dedicating efforts to both current projects and the exploration of new therapeutic areas to address global health challenges.
Snapshot
Operations
Products and/or services of Innoviva
- Trelegy Ellipta, a once-daily triple therapy for COPD and asthma management.
- Anoro Ellipta, a bronchodilator duo for improving breathing in COPD patients.
- Relvar/Breo Ellipta, a combination therapy for asthma and COPD treatment.
- Incivo, a medication designed to treat chronic hepatitis C virus.
Innoviva executive team
- Mr. Pavel Raifeld C.F.A.CEO & Director
- Mr. Stephen Basso M.B.A.Chief Financial Officer
- Ms. Marianne Zhen CPAChief Accounting Officer & Secretary
- Ms. Marcie CainChief People Officer
- Ms. Patricia M. DrakeChief Commercial Officer-Innoviva Specialty Therapeutics, Inc.
- Dr. David Altarac M.D., MPAChief Medical Officer of IST